

Consistent with the terms of the Court's May 22, 2017 scheduling order, the record has been redacted for all information that plaintiff, Texas Department of Criminal Justice (Texas), has identified as confidential. In addition, Defendants have also redacted information that the drug's supplier and broker have separately advised the agency they consider confidential and private, as well as information the agency itself generally treats as confidential. This information has been redacted pending final FDA's review of confidentiality claims, and our filing of the record with these redactions does not necessarily reflect our agreement with all of the claims of confidentiality Defendants have received. Defendants explicitly reserve the right to make an independent determination regarding the proper scope of redactions at a later time. Should we identify any of Texas's redactions that are over-broad or otherwise improper, we will work with Texas's counsel to revise the redactions in the record.

REFERENCE 3








FDA 160



7/28/2015 RES 11

7/28/2015 RES 17









FDA 178




7/28/2015 RES 29









FDA 192



7/28/2015 RES 50



FDA 210

YST TRIP HUBERUSA

DET TROP IS PLICATE